Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
How dying tumor cells get noticed: Besides killing tumor cells directly, some chemotherapies, such as anthracyclines, also activate the immune system to kill tumors. Vacchelli et al. discovered that in mice, anthracycline-induced antitumor immunity requires immune cells to express the protein formyl peptide receptor 1 (FPR1). Dendritic cells (DCs) near tumors expressed especially high amounts of FPR1. DCs normally capture fragments of dying tumor cells and use them to activate nearby T cells to kill tumors, but DCs lacking FPR1 failed to do this effectively. Individuals with breast or colon cancer expressing a variant of FPR1 and treated with anthracyclines showed poor metastasis-free and overall survival. Thus, FPR1 may affect anti-tumor immunity in people, too. Science , this issue p. 972
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This confirmed that Fpr1 deficient immune cells interacted much less with dying cancer cells treated with anthracyclines than immune cells expressing functional Fpr1 (Fig. 3B), explaining why Fpr1 deficiency leads to defective anticancer immune response and less efficient chemotherapy.”
From Microfluidics: A New Tool for Modeling Cancer–Immune Interactions (2016) · cites this paper as [62]
In the citing paper
“Recently, Vacchelli et al. identified a loss of-function mutation in the allele of the gene coding for formyl peptide receptor 1 (Fpr1) that correlated with poor survival in breast and colorectal cancer patients receiving adjuvant chemotherapy[62].”
From Microfluidics: A New Tool for Modeling Cancer–Immune Interactions (2016) · cites this paper as [62]
In the citing paper
“Extracellular ANXA1 reportedly acts as a DAMP and supports the activation of adaptive immune responses by engaging formyl peptide receptor 1 (FPR1) on DCs [876].”
From Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. (2018) · cites this paper as [876]
In the citing paper
“In line with these observations, RCD is not perceived as immunogenic when cancer cells are depleted of HMGB1 or ANXA1, as well as when the host lacks TLR4 or FPR1 [870, 876].”
From Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. (2018) · cites this paper as [876]
Citations
Cites
Fiji: an open-source platform for biological-image analysis
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012) · Nature Methods · doi:10.1038/nmeth.2019 · Cited by 66,890
NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Maere, S., Heymans, K., & Kuiper, M. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bti551 · Cited by 4,155
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Self-citationApetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Self-citationMore powerful procedures for multiple significance testing
Hochberg, Y., & Benjamini, Y. (1990) · Statistics in Medicine · doi:10.1002/sim.4780090710 · Cited by 2,715
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
Self-citationDenkert, C., Loibl, S., Noske, A., Roller, M., Müller, B. M., Komor, M., Budczies, J., Darb-Esfahani, S., Kronenwett, R., Hanusch, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7370 · Cited by 1,762
Cited by
Items 301–400 of 452
Cifrić, S., Turi, M., Folino, P., Clericuzio, C., Barello, F., Maciel, T., Anderson, K. C., & Gullà, A. (2024) · Antioxidants and Redox Signaling · doi:10.1089/ars.2024.0558 · Cited by 12
“…cell;Th17, T helper cell 17; TME, tumor microenvironment; Treg, T regulatory cell. protein (HGMB1) (Yang et al., 2015) and annexin A1 (ANXA1) (Vacchelli et al., 2015), which stimulate DC maturation and crosspresentation, and facilitate the apoptotic body–DC physical interaction, respectively.”
Baka, Z., Stiefel, M., Figarol, A., Godier, C., Mallick, A., Joubert, O., Ashammakhi, N. A., Gaffet, É., & Alem, H. (2022) · Progress in Biomedical Engineering · doi:10.1088/2516-1091/ac8259 · Cited by 15
“In 2015, Vacchelli et al conducted a complex study to investigate molecular mechanisms involved in cancer cell-immune cell interactions and their implications in the development of chemotherapy-induced antitumor immunity [102].”
In Vivo Imaging of Orthotopic Lung Cancer Models in Mice
Liu, P., Zhao, L., Senovilla, L., Kepp, O., & Kroemer, G. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1278-1_16 · Cited by 18
Self-citationZhang, Y., Zhao, H., Deng, W., Lai, J., Sang, K., & Chen, Q. (2024) · Communications Biology · doi:10.1038/s42003-024-06271-w · Cited by 16
“DNMTi-induced immunogenic cell death in tumor cells Accumulating evidence has shown that the capacity of anti-cancer agents to induce ICD is positively correlated with their therapeutic effect 18,27 – 31 .”
Cerrato, G., Liu, P., Zhao, L., Petrazzuolo, A., Humeau, J., Schmid, S. T., Abdellatif, M., Sauvat, A., & Kroemer, G. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02189-3 · Cited by 14
Self-citationPattern Recognition Receptor Polymorphisms as Predictors of Oxaliplatin Benefit in Colorectal Cancer
Gray, V., Briggs, S., Palles, C., Jaeger, E., Iveson, T. J., Kerr, R. S., Saunders, M. P., Paul, J., Harkin, A., McQueen, J., et al. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy215 · Cited by 12
Huang, X., Tang, T., Zhang, G., Hong, Z., Xu, J., Yadav, D. K., Bai, X., & Liang, T. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-00136-1 · Cited by 13
STING-mediated DNA sensing in cancer immunotherapy
Zhou, X., & Jiang, Z. (2017) · Science China Life Sciences · doi:10.1007/s11427-016-9066-0 · Cited by 13
Johnstone, C. N., Tu, Y., Langenbach, S. Y., Baloyan, D., Pattison, A., Lock, P., Britt, K. L., Lehmann, B. D., Beilharz, T. H., Ernst, M., et al. (2021) · Cancers · doi:10.3390/cancers13051154 · Cited by 13
Parameter estimation techniques for a chemotaxis model inspired by Cancer-on-Chip (COC) experiments
Braun, E. C., Bretti, G., & Natalini, R. (2021) · International Journal of Non-Linear Mechanics · doi:10.1016/j.ijnonlinmec.2021.103895 · Cited by 18
Expression and Functions of Formyl Peptide Receptor 1 in Drug-Resistant Bladder Cancer
Jiang, X., Lei, T., & Zhang, M. (2018) · Technology in Cancer Research & Treatment · doi:10.1177/1533034618769413 · Cited by 12
Rs867228 in FPR1 accelerates the manifestation of luminal B breast cancer
Carbonnier, V., Naour, J. L., Bachelot, T., Vacchelli, E., André, F., Delaloge, S., & Kroemer, G. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2189823 · Cited by 11
Self-citationCancer Vaccine in Cold Tumors: Clinical Landscape, Challenges, and Opportunities
Rezaei, M., Danilova, N. D., Soltani, M., Savvateeva, L. V., Tarasov, V. V., Ganjalıkhani-Hakemi, M., Bazhin, A. V., & Zamyatnin, A. A. (2022) · Current Cancer Drug Targets · doi:10.2174/1568009622666220214103533 · Cited by 12
Tressler, A. B., Lane, G. S., & Dubyak, G. (2017) · Molecular Pharmacology · doi:10.1124/mol.116.104000 · Cited by 14
Mencattini, A., Ninno, A. D., Mancini, J., Businaro, L., Martinelli, E., Schiavoni, G., & Mattei, F. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.06.012 · Cited by 13
Self-citationKirtek, T. J., Hamdan, H., Arnam, J. S. V., Park, S. I., Kovach, A. E., Pillai, V., & Weinberg, O. K. (2023) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.14042 · Cited by 11
A major genetic accelerator of cancer diagnosis: rs867228 in FPR1
Sztupinszki, Z. M., Naour, J. L., Vacchelli, E., Laurent‐Puig, P., Delaloge, S., Szállási, Z., & Kroemer, G. (2021) · OncoImmunology · doi:10.1080/2162402x.2020.1859064 · Cited by 11
Self-citationImmunogenic Cell Stress and Death Sensitize Tumors to Immunotherapy
Kepp, O., & Kroemer, G. (2023) · Cells · doi:10.3390/cells12242843 · Cited by 11
“The final approximation of DCs towards dying cancer cells is facilitated by tumor-emitted annexin A1 (ANXA1), which acts on the formyl peptide receptor-1 (FPR1) present on DCs [24].”
BackgroundSelf-citationBoussommier-Calleja, A. (2020) · Bioengineering Innovative Solutions for Cancer · doi:10.1016/b978-0-12-813886-1.00013-9 · Cited by 10
[Advances in Combination Therapy of Immune Checkpoint Inhibitors for Lung Cancer].
Guo, H., Bai, R., & Cui, J. (2020) · PubMed Central · doi:10.3779/j.issn.1009-3419.2020.02.05 · Cited by 12
Quantification of eIF2alpha phosphorylation during immunogenic cell death
Bezu, L., Chuang, A. W., Humeau, J., Kroemer, G., & Kepp, O. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.04.010 · Cited by 13
Self-citationCerrato, G., Liu, P., Martins, I., Kepp, O., & Kroemer, G. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.07.021 · Cited by 12
Self-citationAdvances and challenges in cancer immunotherapy: Strategies for personalized treatment
Azmal, M., Miah, M. M., Prima, F. S., Paul, J. K., Haque, A. S. N. B., & Ghosh, A. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152345 · Cited by 13
A modular metalloprotein in situ vaccine for cancer immunotherapy in mouse models of breast cancer
Liu, D., Jing, T., Yu, L., Luo, H., Rong, H., Tong, Y., Gao, X., & Yin, J. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adr1777 · Cited by 13
Oncolytic Virotherapy and Immunogenic Cell Death: Mechanisms, Platforms, and Clinical Translation
Inoue, H. (2026) · Viruses · doi:10.3390/v18040461 · Cited by 12
Lüke, F., Harrer, D. C., Hahn, J. R., Grube, M., Pukrop, T., Herr, W., Reichle, A., & Heudobler, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.599552 · Cited by 9
“Also, in a breast cancer model, intratumoral dendritic cells could enhance efficacy of anthracyclines highlighting the interaction of immune cells and cytotoxic therapy (Vacchelli et al., 2015).”
BackgroundChen, S., Shen, B., Wu, Y., Shen, L., Qi, H., Cao, F., Huang, T., Tan, H., Wen, C., & Fan, W. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110228 · Cited by 9
Methods to Detect Immunogenic Cell Death In Vivo
Yamazaki, T., Buqué, A., Rybstein, M. D., Chen, J., Sato, A., & Galluzzi, L. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9773-2_20 · Cited by 9
Liu, P., Zhao, L., Ferrere, G., Alves-Costa-Silva, C., Ly, P., Wu, Q., Tian, A.-L., Derosa, L., Zitvogel, L., Kepp, O., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1789284 · Cited by 10
Self-citationChiang, S., Huang, K. C., Chen, W. T., Chen, T.-W., Ke, T., & Chao, K. S. C. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1926074 · Cited by 9
Transcriptome sequencing analysis of mono‑ADP‑ribosylation in colorectal cancer cells
Zhang, N., Lin, T., Xiao, M., Li, Q., Li, X., Yang, L., Wang, C., & Wang, Y. (2020) · Oncology Reports · doi:10.3892/or.2020.7516 · Cited by 8
Strategy and application of manipulating DCs chemotaxis in disease treatment and vaccine design
Lu, Y., & You, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114457 · Cited by 8
Li, Y., Ma, P., Li, J., Wu, F., Guo, M., Zhou, E., Song, S., Wang, S., Zhang, S., & Jin, Y. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01254-0 · Cited by 9
“…and activated DCs) and relatively fewer immunosuppressive cells (such as FOXP3 + Tregs and myeloid-derived suppressor cells) exhibit a favorable prognosis [12, 54, 55]; (ii) anti-cancer therapy (such as ICD inducers) is particularly efficient if local anti-cancer immunity is activated [12, 56].”
BackgroundDhaffouli, F., Hachicha, H., Abida, O., Gharbi, N., Elloumi, N., Kanoun, H., Belguith, N., Marzouk, S., Fakhfakh, R., Feki, S., et al. (2022) · Clinical Rheumatology · doi:10.1007/s10067-022-06057-7 · Cited by 8
Naour, J. L., Sztupinszki, Z. M., Carbonnier, V., Casiraghi, O., Marty, V., Galluzzi, L., Szállási, Z., Kroemer, G., & Vacchelli, E. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2059878 · Cited by 8
“In the past, we observed that a set of single-nucleotide polymorphisms (SNPs) affecting a set of genes involved in the immunogenic cell death (ICD) process dictate the response to adjuvant chemotherapy of breast and colorectal cancer patients.(66,67) This process involves pattern recognition receptors (such as formyl…”
BackgroundSelf-citationAn Agent-Based Interpretation of Leukocyte Chemotaxis in Cancer-on-Chip Experiments
Bretti, G., & Gaetano, A. D. (2022) · Mathematics · doi:10.3390/math10081338 · Cited by 8
Germline Genetics in Immuno-oncology: From Genome-Wide to Targeted Biomarker Strategies
Kirchhoff, T., & Ferguson, R. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9773-2_4 · Cited by 9
Smad7 is a negative regulator of immunogenic cell death in colorectal cancer
Maresca, C., Franzè, E., Laudisi, F., Colella, M., Iannucci, A., Frascatani, R., Monteleone, I., Stolfi, C., & Monteleone, G. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2490346 · Cited by 7
“9,10 ICD is preceded by another major premortem phenomenon, namely autophagy, which favors the lysosomal secretion of ATP in the extracellular space, thus promoting the recruitment of DC into the tumor bed.”
Medrano, R. F. V., Salles, T. A., Dariolli, R., Antunes, F., Feitosa, V. A., Hunger, A., Catani, J. P. P., Mendonça, S. A., Tamura, R. E., Lana, M. G., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-17775-y · Cited by 9
Hijazi, N., Ledersnaider, M., Simanovich, E., Kassem, S., & Rahat, M. A. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.3a0520-333r · Cited by 6
Assessment of eIF2α phosphorylation during immunogenic cell death
Bezu, L., Humeau, J., Leduc, M., Pan, H., Kroemer, G., & Kepp, O. (2022) · Methods in cell biology · doi:10.1016/bs.mcb.2022.01.003 · Cited by 7
Self-citationPreconditioning with immunogenic cell death-inducing treatments for subsequent immunotherapy
Pan, H., Liu, P., Kroemer, G., & Kepp, O. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2023.06.001 · Cited by 7
Self-citationDong, W., Zhao, H., Xiao, S., Zheng, L., Fan, T., Wang, L., Zhang, H., Hu, Y., Yang, J., Wang, T., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1263633 · Cited by 8
Reed-McBain, C. A., Turaga, R. V., Zima, S. R. T., Patel, J. D., Faletti, A., Mixdorf, J. C., Wehner, L. E., Engle, J. W., Hernandez, R. T., Rehen, S. K., et al. (2025) · Biofabrication · doi:10.1088/1758-5090/ade1fb · Cited by 6
Liu, Z., Xu, X., Wang, M., Zhang, J., Zhao, X., Wang, M., Liu, F., & Liu, Z. (2026) · Cell Death Discovery · doi:10.1038/s41420-026-03012-2 · Cited by 6
Immunological consequences of chemotherapy: implications for cancer immunotherapy
Bishara, G. G., Umphred-Wilson, K., Abrams, S. I., Ohm, J. E., & Olejniczak, S. H. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014099 · Cited by 5
“53 Conversely, loss- of-function polymorphisms for DAMP receptors (FPR1, 54 P2RX7 55 ) are associated with poor survival and relapse in patients with breast and CRC. Interestingly, patients with breast cancer with loss- of-function mutations in TLR4, which cannot bind HMGB1, do not exhibit…”
Zhang, J., Ding, T., Tang, D., Wang, J., & Huang, P. (2021) · Experimental Biology and Medicine · doi:10.1177/15353702211047451 · Cited by 5
A Scenario-Based Study on Hybrid PDE-ODE Model for Cancer-on-Chip Experiment
Bretti, G., Campanile, E., Menci, M., & Natalini, R. (2024) · SEMA SIMAI Springer series · doi:10.1007/978-3-031-60773-8_3 · Cited by 6
Sikorski, E. L., Wehr, J., Ferraro, N. J., Rizzo, S., Pires, M. M., & Thévenin, D. (2022) · ChemBioChem · doi:10.1002/cbic.202100521 · Cited by 5
Promises and Challenges of Immunogenic Chemotherapy in Multiple Myeloma
Johnstone, M. E., Vinaixa, D., Turi, M., Morelli, E., Anderson, K. C., & Gullà, A. (2022) · Cells · doi:10.3390/cells11162519 · Cited by 6
Meng, Y., Jin, Z., Wang, M., Chen, D., Zhu, M., Huang, Y., Xia, S., & Xiong, Z. (2023) · Biochemical Genetics · doi:10.1007/s10528-023-10361-5 · Cited by 5
“…(CALR) (Obeid et al. 2007), secreted ATP (Elliott et al. 2009), high-mobility group box 1 (HMGB1) (Conte et al. 2017), type I interferon (Hunger et al. 2017), and cancer cell-derived nucleic acids annexin A1(ANXA1) (Vacchelli et al. 2015), which can induce immune responses to cellular antigens.”
BackgroundGong, J., Yu, R., Hu, X., Luo, H., Gao, Q., Li, Y., Tan, G., Luo, H., & Qin, B. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s424545 · Cited by 5
Park, D., Park, I., Han, B., Baek, Y., Moon, D., Jeon, N. L., & Doh, J. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0263 · Cited by 6
The non-T-cell-inflamed tumor microenvironment: contributing factors and therapeutic solutions
Horton, B. L., & Spranger, S. (2017) · Emerging Topics in Life Sciences · doi:10.1042/etls20170073 · Cited by 5
Immunogenic Stress and Death of Cancer Cells in Natural and Therapy-Induced Immunosurveillance
Kepp, O., Pol, J. G., Zitvogel, L., & Kroemer, G. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_12 · Cited by 6
Self-citationGermline genetic host factors as predictive biomarkers in immuno-oncology
Chat, V., Ferguson, R., & Kirchhoff, T. (2019) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2019.08.001 · Cited by 6
Yin, L., Zhang, W., Pu, D., Zhai, X., Lin, Y., Wu, Q., Chang, T. C., Hu, J., Li, Y., & Zhou, Q. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.778549 · Cited by 5
“org 5 functions of neutrophils, including chemotaxis, degranulation, ROS production, and phagocytosis (22).”
BackgroundNo impact of cancer and plague-relevant FPR1 polymorphisms on COVID-19
Petrazzuolo, A., Naour, J. L., Vacchelli, E., Gaussem, P., Ellouze, S., Jourdi, G., Solary, É., Fontenay, M., Smadja, D. M., & Kroemer, G. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1857112 · Cited by 7
Self-citationAn unexpected link between immunogenic cell death and inhibition of gene transcription
Humeau, J. F., Sauvat, A., Kepp, O., & Kroemer, G. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1792039 · Cited by 5
Self-citationPan, Y., Zhao, L., Liu, J., Mao, M., Tian, A.-L., Naour, J. L., Scuderi, S. A., Pan, H., Doffe, F., Naylor, D., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102683 · Cited by 4
“15 15–18 Accordingly, in Fpr1 − / − mice, anticancer chemotherapy with immunogenic cytotoxicants (such as doxorubicin, oxaliplatin, or mitoxantrone) fails in conditions in which tumors implanted in wild-type (WT) controls do respond.”
InfluentialSelf-citationA microfluidic device for shape measurement in red blood cells (RBCs)
Mencattini, A., Giuseppe, D. D., D’Orazio, M., Rizzuto, V., Pereira, M. M., Comes, M. C., Lopez-Martinez, M. J., Samitier, J., & Martinelli, E. (2020) · IEEE International Symposium on Medical Measurements and Applications (MeMeA) · doi:10.1109/memea49120.2020.9137212 · Cited by 3
Zhao, L., Zhang, S., Chen, H., Kroemer, G., Kepp, O., & Liu, P. (2022) · Methods in cell biology · doi:10.1016/bs.mcb.2021.12.027 · Cited by 4
Self-citationA fluorescent photoaffinity probe for formyl peptide receptor 1 labelling in living cells
Field, D. H. H., White, J. S., Warriner, S. L., & Wright, M. H. (2023) · RSC Chemical Biology · doi:10.1039/d2cb00199c · Cited by 4
Formyl peptide enhances cancer immunotherapy by activating antitumoral neutrophils, and T cells
Sun, H., Li, S., Wang, Q.-L., Luo, C., Zhong, L., Wan, G., Li, Z., Zhao, G., Bu, X., Zeng, M., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116670 · Cited by 6
Kulig, P., Łuczkowska, K., Machaliński, B., & Baumert, B. (2024) · Scientific Reports · doi:10.1038/s41598-024-74558-3 · Cited by 4
Antagonism and negative side-effects in combination therapy for cancer
Friedman, A., & Lai, X. (2019) · Discrete and Continuous Dynamical Systems - B · doi:10.3934/dcdsb.2019093 · Cited by 5
Seyfoori, A., Barough, M. S., Amereh, M., Jush, B. K., Lum, J. J., & Akbari, M. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.11.028 · Cited by 5
Kepp, O., & Kroemer, G. (2020) · Nature Cancer · doi:10.1038/s43018-020-00107-2 · Cited by 4
Self-citationGetting Tumor Dendritic Cells to Engage the Dead
Cucolo, L., & Minn, A. J. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.11.009 · Cited by 5
“The study by Vacchelli et al. (2015) makes important contributions toward understanding the cellular events that occur after effective chemotherapyinduced ICD (Figure 1).”
BackgroundInfluentialImmunogenic Cell Death Genes Related Prognostic Biomarker in Hepatocellular Carcinoma
Bi, F., Yang, S., He, Z., Dai, Y.-S., Zou, R.-Q., Hu, Y.-F., Hu, H., & Li, F. (2025) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2025.061422 · Cited by 3
“As a controlled mode of cell death, ICD stimulates T cell-driven adaptive immunity, reactivates immune surveillance, and remodels the immunosuppressive tumor microenvironment, ultimately producing a sustained tumor-inhibitory effect [9,16].”
Clavero, A. L., Kopsida, M., Arendt, N., Lennernäs, H., Sjöblom, M., & Heindryckx, F. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118859 · Cited by 3
Immunogenic cell death as a cornerstone for combination therapies with immune checkpoint blockade
Niu, Y., Zhu, S., Fu, K., Lai, Y. Y., Pan, C., Yang, Y., Li, S., Wang, X., To, K. F., Wang, F., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02663-0 · Cited by 7
“It directs DCs migration to the tumor site by interacting with formyl peptide receptor 1 (FPR1) on DCs [93].”
Shao, Y., Wang, Z., Wu, J., Lu, Y., Chen, Y., Zhang, H., Huang, C., Shen, H., Xu, L., & Fu, Z. (2023) · Functional & Integrative Genomics · doi:10.1007/s10142-023-01238-2 · Cited by 5
“Dendritic cells mature and migrate to the tumor bed, engulf tumor antigens, and present them to T cells after receiving signals from DAMPs (Kepp et al. 2021; Vacchelli et al. 2015; Apetoh et al. 2007).”
Investigation of tumour environments through advancements in microtechnology and nanotechnology
Liu, Z., Fan, Y. L., Cui, M., Wang, X., & Zhao, P. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117230 · Cited by 4
Raggi, C., Spadaro, F., Mattei, F., Gambardella, A. R., Noto, F., Andreone, S., Signore, M., Schiavoni, G., Parolini, I., & Afferni, C. (2024) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiae232 · Cited by 3
Self-citationSchmitz, E. G., Ridout, A., Smith, A. L., Eiken, A. P., Skupa, S. A., Drengler, E. M., Singh, S., Rana, S., Natarajan, A., & El-Gamal, D. (2024) · Biomedicines · doi:10.3390/biomedicines12122857 · Cited by 3
Pompa, M., Torre, D. L., Bretti, G., & Gaetano, A. D. (2023) · Axioms · doi:10.3390/axioms12100930 · Cited by 4
Method for quantitative detection of FAM19A4 by flow cytometry using latex beads as solid carrier
Li, T., Wang, W., Cheng, Y., & Han, W. (2017) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2017.10.008 · Cited by 3
“It may play crucial roles in pain relief and pathogenic infections and probably be involved in antitumor immunity as well (1,7,9).”
BackgroundKeeping Cell Death Alive: An Introduction into the French Cell Death Research Network
Ichim, G., Gibert, B., Adriouch, S., Brenner, C., Davoust, N., Desagher, S., Devos, D., Dokudovskaya, S., Dubrez, L., Estaquier, J., et al. (2022) · Biomolecules · doi:10.3390/biom12070901 · Cited by 3
Self-citationJiang, X., Asad, M., Li, L., Sun, Z., Milanese, J., Liao, B., & Wang, E. (2020) · Quantitative Biology · doi:10.1007/s40484-020-0212-7 · Cited by 4
Editorial: Breast Cancer Patient-Derived Xenografts: Pros, Cons, and Next Steps
Shafaee, M. N., & Ellis, M. J. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw307 · Cited by 3
Development of therapeutic cancer vaccines based on cancer immunity cycle
Zhang, J., Zheng, Y., Xu, L., Gao, J., Ou, Z., Zhu, M., & Wang, W. (2025) · Frontiers of Medicine · doi:10.1007/s11684-025-1134-6 · Cited by 2
Tian, M., Liu, S., Li, X., Chai, Z., Li, Z., Fan, H., Zhu, C., Wu, K., & Lan, K. (2026) · Vita · doi:10.15302/vita.2026.01.0005 · Cited by 4
Immunogenic Cell Death in Cancer
Humeau, J., Naour, J. L., Kroemer, G., & Pol, J. G. (2023) · Interdisciplinary cancer research · doi:10.1007/16833_2022_121 · Cited by 2
Self-citationSupramolecular immunotherapy on diversiform immune cells
Wang, J., Zhang, Z., & Chen, Y. (2023) · Journal of Materials Chemistry B · doi:10.1039/d3tb00924f · Cited by 2
Novizio, N., Belvedere, R., Palazzo, M., Varricchio, S., Merolla, F., Staibano, S., Ilardi, G., & Petrella, A. (2025) · Cancers · doi:10.3390/cancers17071058 · Cited by 2
Tsai, Y.-F., Yang, S.-C., & Hwang, T. (2025) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2025.2515882 · Cited by 2
“FPR1 polymorphisms are associated with an increased susceptibility to stomach cancer [98].”
Microfluidics: A New Tool for Modeling Cancer-Immune
Boussommier-Calleja, I., Li, R., Chen, M. B., & Kamm, R. D. (2016) · Cited by 2
Çetin, B., Bilgetekin, İ., & Özet, A. (2018) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2018.07.008 · Cited by 3
Cytofluorometric assessment of dendritic cell-mediated uptake of cancer cell apoptotic bodies
Musella, M., Manic, G., Galassi, C., Vitale, I., & Sistigu, A. (2020) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.08.005 · Cited by 3
Self-citationMattei, F., George, J. T., & Jolly, M. K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1253551 · Cited by 2
Self-citationChang, C., Huang, K. C., Chen, T.-W., Chen, W. T., Ke, T., Liou, Y., Chao, K. S. C., & Chiang, S. (2023) · In Vivo · doi:10.21873/invivo.13240 · Cited by 1
Campanile, E., Colombi, A., & Bretti, G. (2024) · Mathematical Biosciences · doi:10.1016/j.mbs.2024.109330 · Cited by 2
Monoclonal Antibody 5F1 Modulates Formyl Peptide Receptor 1 Conformation for Transmembrane Signaling
Wang, Y., Liu, Y., Chang, Y., & Ye, R. D. (2025) · FASEB BioAdvances · doi:10.1096/fba.2025-00145 · Cited by 1
Филимонова, М. В., Васильевна, С. О., Андреевна, Ш. А., Surinova, V., Александрович, Р. В., Kosachenko, A. O., Анатольевич, Н. К., Filatova, D., Prosovskaya, E., Иванов, С. А., et al. (2025) · Molecules · doi:10.3390/molecules30183710 · Cited by 1
“…cells) and the induction of T-cell-dependent immune responses (inhibition of immunosuppressive Treg cells, decreased levels of immunosuppressive cytokines, recovery of IFN-γ -producing NK cells, polarization of Th1 and Th17 lymphocytes and macrophages, and activation of dendritic cells) [40–46].”
Tang, Z., Huang, T., & Yang, T.-L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311596 · Cited by 5
“Additional mediators include transcription factor A mitochondrial and formyl peptide receptor 1, with FPR1-deficient DCs showing impaired responses [61].”
Marotta, M., Liotti, F., Melillo, R. M., & Prevete, N. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1733396 · Cited by 1
Validation of an agent-based model for cell interactions in a microfluidic chip
Panunzi, S., Pompa, M., D’Angelo, P. M., Bretti, G., & Gaetano, A. D. (2026) · PLoS ONE · doi:10.1371/journal.pone.0341962 · Cited by 1
“In that experiment, pretreated human breast cancer cells and peripheral blood mononuclear cells were cultured [19].”
InfluentialDeng, Z., Zhang, C., Wei, H., Hu, Z., Hua, G., Li, Z., Wu, J., He, T., Wang, Y., CAI, Y., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-25-3669 · Cited by 1
Wang, X., Guo, L., Yuan, M., Feng, Y. P., Wang, Y., & Jin, G. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04270-x · Cited by 1
“…demonstrated that mitoxantrone and doxorubicin can significantly induce the expression of ANXA1 in tumor tissues; moreover, the inhibitory effect of anthracyclines on tumor growth in vivo was completely abrogated following the blockade of extracellular ANXA1 using neutralizing antibodies [39].”
Metadata
- Authors
- Vacchelli, E., Ma, Y., Baracco, E. E., Sistigu, A., Enot, D. P., Pietrocola, F., Yang, H., Adjemian, S., Chaba, K., Semeraro, M., Signore, M., De Ninno, A., Lucarini, V., Peschiaroli, F., Businaro, L., Gerardino, A., Manic, G., Ulas, T., Günther, P., Schultze, J. L., Kepp, O., Stoll, G., Lefebvre, C., Mulot, C., Castoldi, F., Rusakiewicz, S., Ladoire, S., Apetoh, L., Bravo-San Pedro, J. M., Lucattelli, M., Delarasse, C., Boige, V., Ducreux, M., Delaloge, S., Borg, C., André, F., Schiavoni, G., Vitale, I., Laurent-Puig, P., Mattei, F., Zitvogel, L., & Kroemer, G.
- Affiliations
- Inserm (FR)
- Instituto Nazionale Tumori Regina Elena (IT)
- Gustave Roussy Cancer Campus, Villejuif, France.
- Istituto Superiore di Sanità (IT)
- Italian National Research Council, Institute for Photonics and Nanotechnology, Rome, Italy.
- National Research Council (IT)
- University of Bonn (DE)
- Centre Georges François Leclerc (FR)
- Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.
- University of Siena (IT)
- Centre National de la Recherche Scientifique (FR)
- Université Paris-Saclay (FR)
- University of Rome Tor Vergata (IT)
- Université Paris Sorbonne Cité, UMRS 775, INSERM, Paris, France.
- Karolinska University Hospital (SE)
- Corresponding author
- Zitvogel, Laurence
- ORCID
- Vacchelli, Erika
- Ma, Yuting
- Sistigu, Antonella
- Pietrocola, Federico
- Yang, Heng
- Adjemian, Sandy
- Signore, Michele
- Businaro, Luca
- Gerardino, Annamaria
- Manic, Gwenola
- Ulas, Thomas
- Günther, Patrick
- Schultze, Joachim L.
- Kepp, Oliver
- Stoll, Gautier
- Mulot, Claire
- Castoldi, Francesca
- Rusakiewicz, Sylvie
- Ladoire, Sylvain
- Lucattelli, Monica
- Delarasse, Cécile
- Boige, Valérie
- Ducreux, Michel
- Delaloge, Suzette
- Borg, Christophe
- André, Fabrice
- Schiavoni, Giovanna
- Vitale, Ilio
- Mattei, Fabrizio
- Zitvogel, Laurence
- Kroemer, Guido
- Venue
- Science
- Published
- 2015-11-20
- Volume
- 350
- Issue
- 6263
- Pages
- 972-978
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1911271782
- Cited by
- 452
- References
- 40
- Citations by year
- 2026: 25 · 2025: 25 · 2024: 29 · 2023: 51 · 2022: 38 · 2021: 50 · 2020: 58 · 2019: 47 · 2018: 45 · 2017: 40 · 2016: 42 · 2015: 1
- FWCI
- 20.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Funders
- Agence Nationale de la Recherche (ANR-10-LABX-0015, ANR-10-INBS-0001, ANR-10-IBHU-0001)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- FPR1, anthracycline chemotherapy, antitumor immunity, annexin A1, cancer cell death, T cell immunity, breast cancer, colorectal cancer, adjuvant chemotherapy, loss-of-function alleles, microfluidics, metastasis-free survival
- MeSH terms
- Alleles, Animals, Breast Neoplasms, Dendritic Cells, Female, Humans, Immunity, Innate, Leukocytes, Neoplasms, T-Lymphocytes, Colorectal Neoplasms, Chemotherapy, Adjuvant, Annexin A1, Anthracyclines, Polymorphism, Single Nucleotide, Receptors, Formyl Peptide, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.